ATE153854T1 - Stabile pharmazeutische zubereitung mit fumagillolderivaten - Google Patents

Stabile pharmazeutische zubereitung mit fumagillolderivaten

Info

Publication number
ATE153854T1
ATE153854T1 AT93120104T AT93120104T ATE153854T1 AT E153854 T1 ATE153854 T1 AT E153854T1 AT 93120104 T AT93120104 T AT 93120104T AT 93120104 T AT93120104 T AT 93120104T AT E153854 T1 ATE153854 T1 AT E153854T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparation
preparation containing
stable pharmaceutical
fumagillol derivatives
fumagillol
Prior art date
Application number
AT93120104T
Other languages
English (en)
Inventor
Shigeo Yanai
Kazuhiro Saito
Hiroaki Okada
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE153854T1 publication Critical patent/ATE153854T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
AT93120104T 1992-12-16 1993-12-14 Stabile pharmazeutische zubereitung mit fumagillolderivaten ATE153854T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33582892 1992-12-16

Publications (1)

Publication Number Publication Date
ATE153854T1 true ATE153854T1 (de) 1997-06-15

Family

ID=18292862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93120104T ATE153854T1 (de) 1992-12-16 1993-12-14 Stabile pharmazeutische zubereitung mit fumagillolderivaten

Country Status (8)

Country Link
US (1) US5422363A (de)
EP (1) EP0602586B1 (de)
KR (1) KR940013499A (de)
CN (1) CN1093901A (de)
AT (1) ATE153854T1 (de)
CA (1) CA2111560A1 (de)
DE (1) DE69311278T2 (de)
PH (1) PH30120A (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5566069A (en) * 1994-03-07 1996-10-15 Monsanto Company Computer network for collecting and analyzing agronomic data
US5699244A (en) * 1994-03-07 1997-12-16 Monsanto Company Hand-held GUI PDA with GPS/DGPS receiver for collecting agronomic and GPS position data
EP0799616A1 (de) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Orale Zubereitung enthaltend ein Fumagillolderivat
US20010025046A1 (en) * 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
PT1156829E (pt) 1999-02-26 2007-08-17 Sanofi Aventis ''formulação estável contendo fumagilina''
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
AU3947902A (en) * 2000-11-01 2002-06-03 Praecis Pharm Inc Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7001603B2 (en) * 2001-02-28 2006-02-21 Color Access, Inc. Gelled two phase cosmetic compositions
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
JP2007537147A (ja) * 2003-12-29 2007-12-20 プレーシス ファーマスーティカルズ インコーポレイテッド メチオニンアミノペプチダーゼ−２のインヒビターおよびその使用
NZ585547A (en) * 2007-11-28 2012-12-21 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
AU2009270799B2 (en) * 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
EP2521719B1 (de) 2010-01-08 2015-07-29 Zafgen, Inc. Fumagillol-verbindungen sowie verfahren zu ihrer herstellung und verwendung
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
KR101892768B1 (ko) 2010-11-09 2018-08-28 자프겐 인크. Metap-2 저해제의 결정질 고체 및 그의 제조 및 이용 방법
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
EP2646016B1 (de) 2010-11-29 2017-05-17 Zafgen, Inc. Behandlung von fettleibigkeit mittels nicht-täglicher verabreichung von - 6 - 0 - (4 - dimethylaminoethoxy)-cinnamoylfumagillol
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
KR101875988B1 (ko) 2011-03-08 2018-07-06 자프겐 인크. 옥사스피로[2.5]옥탄 유도체 및 유사체
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
KR20150016303A (ko) 2012-05-07 2015-02-11 자프겐 인크. 6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
CA2872876A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
KR20150016534A (ko) 2012-05-09 2015-02-12 자프겐 인크. 푸마지롤형 화합물 및 이의 제조 및 사용 방법
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
MX2015005732A (es) 2012-11-05 2015-12-16 Zafgen Inc Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
KR20150126924A (ko) 2013-03-14 2015-11-13 자프겐 인크. 신장 질환 및 기타 장애의 치료 방법
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
BR112019019098A2 (pt) 2017-03-15 2020-04-22 Cerecin Inc composições farmacêuticas tendo altos carregamentos de fármaco de triglicerídeos de cadeia média, seu método de produção e seu uso
BE1027390B1 (nl) 2019-06-21 2021-02-02 Nutrition Sciences Nv Mfca-samenstelling voor gebruik in de aquacultuur van schaaldieren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
JP2806454B2 (ja) * 1988-01-19 1998-09-30 武田薬品工業株式会社 脈管形成阻止剤
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
ES2053890T3 (es) * 1988-09-01 1994-08-01 Takeda Chemical Industries Ltd Agente inhibidor de la angiogenesis.
DE68927904T2 (de) * 1988-09-01 1997-09-04 Takeda Chemical Industries Ltd Fumagillol-Derivate
ATE97410T1 (de) * 1989-03-06 1993-12-15 Takeda Chemical Industries Ltd 6-amino-6-desoxyfumagillole, ihre herstellung und ihre verwendung.
DE69001187T2 (de) * 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (de) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.

Also Published As

Publication number Publication date
EP0602586A2 (de) 1994-06-22
KR940013499A (ko) 1994-07-15
US5422363A (en) 1995-06-06
DE69311278D1 (de) 1997-07-10
CA2111560A1 (en) 1994-06-17
PH30120A (en) 1996-12-27
CN1093901A (zh) 1994-10-26
EP0602586A3 (de) 1994-08-31
DE69311278T2 (de) 1997-10-30
EP0602586B1 (de) 1997-06-04

Similar Documents

Publication Publication Date Title
ATE153854T1 (de) Stabile pharmazeutische zubereitung mit fumagillolderivaten
FI863652A (fi) 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning.
CA2156288A1 (en) Glycerol derivative, device and pharmaceutical composition
DE3875425D1 (de) Vasokinetisch wirkende polyungesaettigte saeuren und sie enthaltende pharmazeutische oder kosmetische zubereitungen.
DE68901043D1 (de) Waessriges pharmazeutisches praeparat.
ES2080549T3 (es) Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo.
FI895045A0 (fi) Menetelmä ihon kautta annettavan bunatsosiinia sisältävän farmaseuttisen valmisteen valmistamiseksi
FI905748A (fi) Foerfarande foer framstaellning av 4-o -fosfater av dopamin och dopaminderivat.
DK585889A (da) Farmaceutisk praeparat
DK0657164T3 (da) Farmaceutiske præparater indeholdende staurosporinderivater og et polyalkylenglycolglycerid
DK199789A (da) Anvendelse af et phenylquinolincarboxylsyrederivat eller et farmaceutisk egnet salt deraf til fremstilling af et topisk farmaceutisk praeparat til behandling af hud- og/eller slimepithelsygdomme
FI932769A (fi) Farmaceutisk komposition med foerbaettrad biotillgaenglighet och innehaollande probukol
FR2681863B1 (fr) Solution de sparfloxacine sa preparation et sel la constituant.
YU108691A (sh) Nove 3,3'-ditiobis (propionske kiseline) i njihovi estri
FI933477A (fi) Monohydrat av ett dinatriumsalt av 4-klorfenyltiometylenbisfosfonsyra,dess framstaellning och farmaceutiska kompositioner innehaollande detta
FR2691149B1 (fr) Nouveaux composes thiochromaniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
ATE120734T1 (de) Glyzerin-derivat und dessen pharmazeutische verwendung.
NO171912C (no) Fremgangsmaate for fremstilling av 5-klor-3-klorsulfonyl-2-tiofenkarboksylsyreestere
DE69009211D1 (de) Derivate von Thiazolidin-4-carbonsäure, deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
NO892495L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparat.
NO870950L (no) FremgangsmŸte for fremstilling av et stabilt injiserbart farmasŸytisk preparat.
SE8104657L (sv) Injicerbara farmaceutiska kompositioner
ATE120731T1 (de) Optisch aktives derivat der d-2-(6-methoxy-2- naphthyl)-propionsäure und es enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties